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Abstract 
Rheumatoid arthritis (RA) is the most common inflammatory arthropathy.  The majority 
of evidence, derived from genetics, tissue analyses, models and clinical studies, points 
to an immune mediated etiology associated with stromal tissue dysregulation that 
together propogate chronic inflammation and articular destruction.  A pre-RA phase 
lasting months to years, may be characterized by the presence of circulating 
autoantibodies, increasing concentration and range of inflammatory cytokines and 
chemokines and altered metabolism.  Clinical disease onset comprises synovitis and 
systemic comorbidities affecting the vasculature, metabolism and bone.  Targeted 
immune therapeutics, and aggressive treatment strategies have substantially improved 
clinical outcomes, and informed pathogenetic understanding, but no cure as yet exists.  
Herein we review recent data that support intriguing models of disease pathogenesis. 
They allude to the possibility of restoration of immunologic homeostasis and thus a 
state of tolerance associated with drug free remission. This target represents a bold 
vision for the future of RA therapeutics.   
  
 3 
Immune dysregulation was first implicated in the pathogenesis of rheumatoid arthritis 
(RA) by the discovery of anti-immunoglobulin G (IgG) antibodies known as rheumatoid 
factors, initially by Erik Waaler and then more fully described by H. M. Rose in the 
1940s. However, concepts of how immune responses contribute to disease have evolved 
dramatically over the last 50 years. Autoreactivity as a pivotal step dominates the 
conceptual landscape, although other mechanisms, both immunologic and tissue derived 
clearly contribute to disease pathogenesis. Thus, RA is characterized by evidence of 
disordered innate immunity, including immune complex-mediated complement 
activation, adaptive immune responses against ‘self’-antigens comprising predominantly 
post-translationally modified proteins, dysregulated cytokine networks, osteoclast and 
chondrocyte activation and imprinting of resident stromal cells that in turn develop 
semi-autonomous features that support disease progression (Arend & Firestein 2012; 
Firestein 2003).  
 
Based on substantial new data identifying the immunologic and metabolic events that 
precede onset of clinical disease, even by years (i.e., “pre-RA”), and the increasing 
impact of the application of the advanced molecular ‘omics’ revolution to disease 
investigation, an integrated hypothesis for disease pathology is emerging (Catrina et al 
2016; Tan & Smolen 2016). In this review, we will posit that RA starts with a high-risk 
genetic background that, in combination with epigenomic marks that contribute to 
heritability and disease chronicity, and stochastic environmental exposures that create 
neo-epitopes, launches a cascade of events inducing synovitis and ultimately chronic 
destructive arthritis (Figure 1). Based on the diversity of clinical responses to highly 
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targeted therapeutic agents, we propose that RA probably does not comprise a single 
entity. Rather, it is perhaps more appropriately considered a syndrome with a common 
clinical phenotype arising from diverse pathways operating variably, albeit often with 
overlap, in individual patients (Firestein, 2014). 
 
Genetics of Rheumatoid Arthritis 
Genetic factors clearly play a role in RA risk, severity and progression. Monozygotic 
twins share RA on about 12-15% of occasions compared to 1% for the general 
population and around 2-5% for fraternal twins or other first-degree relatives. This 
relatively low concordance implicates many other factors, including those in the 
environment and the microbiome in pathogenesis. Note also that gene sequences are not 
the sole determinant of heritability, and epigenetic marks likely also contribute, 
especially for monozygotic twins (Kaminsky et al 2009). 
 
The most important genetic risk allele for RA resides in the class II major 
histocompatibility (MHC) locus accounting for about 40% of the genetic influence. The 
odds ratio of developing RA in individuals with MHC class II HLA-DR4 alleles is 
about 5:1. This link between HLA-DR and RA was initially described in the 1970s with 
the observation that HLA-DR4 is present in 70% of RA patients, compared with about 
30% of controls.  A so called shared “susceptibility epitope” (SE) was identified in 
amino acids 70 through 74 in the third hypervariable region of the DRβ chain. The 
sequence associated with disease is generally glutamine-leucine-arginine-alanine-
alanine (QKRAA), which is present in some DR4 and DR14, in addition to DR1β 
chains. The SE with the closest links to RA include DRB*0401, DRB*0404, 
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DRB*0101, and DRB*1402. Over 90% of patients with RA express at least one of these 
variants (Weyand et al 1992). The SE is also associated with increased disease severity, 
such as extra-articular manifestations and progression of erosions.  
 
The SE region predominantly faces away from the antigen-binding groove that binds 
processed peptides for presentation to T cells, which has raised some questions about 
their precise contributory role. RA-specific peptides that bind to QKRAA-containing 
molecules have been difficult to identify (Kirschmann et al 1995). This observation led 
to the notion that SE might also partially contribute by shaping the T cell repertoire in 
the thymus, altering intracellular HLA-DR trafficking and antigen loading, or serving as 
an autoantigen. 
 
More recently, linkage disequilibrium and informatics-based studies to understand the 
role of the SE identified additional amino acids located in the base of the antigen 
binding groove as a likely explanation for antigen selection, especially leucine or valine 
variants at amino acid 11 (Raychaudhuri et al 2012). Serine at amino acid 11 confers 
decreased risk for RA. The risk alleles, especially deep within the cleft, could directly 
increase risk via presentation of arthritogenic antigens, such as citrullinated proteins. 
For example, citrullinated vimentin peptides bind much more avidly to the RA HLA-
DR than does native protein; in contrast, other MHCs do not exhibit this differential 
binding (Hill et al 2003; Law et al 2012). Subsequent crystal studies have characterized 
in detail the nature of the citrullinated peptide binding to HLADRB1 (Scally S et al 
2013). RA-associated alleles present citrullinated peptides efficiently to T cells, which, 
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in turn, produce higher amounts of cytokines IL-17 and IFN than to native peptide. 
Adaptive immune responses to citrullinated peptides are also characterized by the 
presence of “anti-citrullinated peptide antibodies” (ACPAs), observed in 80-90% of RA 
patients.   
 
Together these data support the notion that HLA-DR risk for RA is based, at least in 
part on the increased efficiency of antigen presentation for altered peptides rather than 
native proteins (van der Helm et al 2006). Citrullination of peptides in the presence of 
environmental stress is ubiquitous in mammalian cells and is not a unique feature of 
RA. Instead, production of antibodies recognizing citrullinated peptides differentiates 
individuals at risk. The emergence of numerous other post-translationally modified 
protein targets, e.g. via carbamylation or acetylation, recognized by autoantibodies in 
RA is consistent with the notion of altered presentation of post-translationally modified 
peptides; other families of altered peptides could be implicated in discrete subsets of 
patients. 
 
Overall, genome wide association studies (GWAS) studies and meta-genomic analyses 
have identified over 100 single nucleotide polymorphisms (SNPs) and genes associated 
with ACPA+ RA beyond the HLA. RA-associated SNPs tend to cluster around immune 
genes (Okada et al 2014).  The genetic architecture of RA has recently been extensively 
reviewed (Kim et al 2017).  Briefly, individual SNPs usually provide modest 
contribution to risk with odds ratios typically in the 1.05 to 1.2-fold range, though this 
need not infer low functional impact. Combinations of these genes can potentially 
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interact to increase risk. For example, a relatively rare combination of HLA-DR, 
PTPN22, and TRAF1-C5 SNPs increases risk over 40-fold (Firestein & Zvaifler 2002). 
While there are undoubtedly additional combinations or rare variants with high 
penetrance, the contribution of newly identified genes to overall risk is growing 
increasingly small. Notably, meta-analyses of patients with ACPA- RA show some 
differences from ACPA+ disease, consistent with the idea that ‘seronegative RA’ 
should be considered a distinct clinical pathologic entity. 
 
Intriguing individual non-MHC linkages are associated with peptidyl arginase 
deiminase (PADI) and PTPN22. PADI gene products are enzymes that convert arginine 
to citrulline, creating new potential antigens that bind to RA-associated MHC proteins. 
An extended PADI4 haplotype prolongs its mRNA stability and could, therefore, 
increase peptide citrullination (Suzuki et al 2003).  Up to a 2-fold increase in risk of RA 
was observed with PADI4 SNPs in Asian and North American cohorts. The PTPN22 
allele with an amino acid substitution (R620W) doubles the risk of developing ACPA+, 
but not ACPA- RA. This SNP is also associated with many other immune mediated 
diseases, including systemic lupus erythematosus (SLE) and type 1 diabetes (Rawlings 
et al 2015).  The R620W allele is a gain of function change mutation in the PTPN22 
protein, a phosphatase that regulates amongst other signal proteins, Lck and ZAP70. 
Thus, modified T cell receptor signaling could alter either the T cell repertoire in the 
thymus or immune responses, or tolerance in the periphery.  The R620W allele however 
also positively regulates TLR induced type 1 IFN expression in myeloid cells via 
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reduced efficiency of PTPN22W mediated TRAF3 ubiquitination and thus could 
amplify innate cytokine expression to promote disease (Wang et al 2013).  
 
A number of additional genes involved with adaptive immunity have RA-associated 
SNPs in a various populations (Yamamoto et al 2015).  In addition to PTPN22, the co-
stimulation receptors, CTLA and CD28, have emerged from GWAS studies. Other 
genes associated with B cell function and/or antigen presentation such as BTLA (B- and 
T-lymphocyte attenuator), Fc receptors, and CD40 have been identified. Signal 
transduction genes and pathways that regulate immune function such as TRAF1-C5 and 
STAT4, cell migration (ELMO1) and fetal development (LBH) are also identified. 
Finally, multiple gene polymorphisms have been identified in cytokine or cytokine 
receptor coding loci, including TNF. This is especially relevant in light of the pivotal 
role of cytokines in synovitis described below and the consequent efficacy of targeted 
anti-cytokine, and cytokine receptor signal pathway therapeutics. In some cases, the 
causative mutations can alter expression or function. For instance, RA associated TNF 
promoter polymorphisms at positions −238 and −308 can potentially modulate TNF 
gene expression (Fonseca et al 2007).   An IL-6 receptor polymorphism that is 
functionally implicated in the intensity of IL-6 signaling is also associated with RA 
(Ferriera et al 2013).  Thus, the genetic clues to RA pathogenesis implicate 
inflammation, adaptive and innate immunity at the core of pathogenesis.  
 
Interactions between genes and environment: RA as a ‘mucosal disease’? 
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RA is properly considered an immune-mediated disease with a strong genetic influence. 
However, its origins may involve the interface between external influences and the 
immune system, manifest especially at mucosal surfaces. Three sites have been 
associated particularly with RA namely, 1) the lungs, 2) the oral mucosa and 3) the 
gastrointestinal tract. Whereas precise mechanisms that enhance risk are not fully 
understood for each, it is likely that local tissue stress leads to post-translational 
modification of peptides with subsequent antibody formation serving as a common 
mechanism.  
 
Epidemiologic /genetic studies, particularly those arising from impressive Swedish 
registries have highlighted the role of cigarette smoking as a prominent environmental 
risk factor for RA, pointing to a role for pulmonary mucosal biology in disease 
aetiology. The amount and duration of smoking are important, with the highest risk 
observed with greater than 20 pack-years of exposure. Risk declines slowly back to 
normal within 10 years of smoking cessation (Kallberg et al 2011), suggesting that 
effects are not solely toxin dependent but may also arise by altering immunologic 
function. Notably, other pulmonary exposures can replace smoking in increasing risk 
e.g., silica or textile dust. Nevertheless, mechanisms underlying the relationship with 
smoking are uncertain (Catrina AI et al 2014). Exposure to inhaled toxic chemicals in 
cigarette smoke can potentially increase PADI expression in the airway and increase 
protein citrullination (Vassalo et al 2014).  Smoking related risk interacts in a 
synergistic manner with MHC risk alleles. The QKRAA-containing HLA chains alone 
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modestly increase the likelihood of developing RA 4- to 6-fold, but this risk increases 
up to 20- to 40-fold when combined with smoking (Lundstrom et al 2009).   
 
Thus in individuals carrying risk HLA alleles, such peptides could be more efficiently 
presented and ACPAs generated via subsequent T-B cell help. Alternatively, ‘innate’ B 
cell subsets could initiate responses to modified self-peptides, and thereafter present 
peptide to T cells. In this model, production of “autoantibodies” could result from 
“auto-reactive” T cell clones that are available to respond to modified peptides because 
they were not deleted during development since the altered proteins/peptides were not 
present in the thymus (Linn-Rasker et al 2006).  A corollary to this would be that a 
major immunologic regulatory deficit in RA patients is a failure to regulate T cell 
recognition of post-translationally modified self-proteins across a range of specificities 
– as observed above, this is compatible with the expression of a relatively broad 
autoantibody spectrum in clinical disease. 
 
Broncho-alveolar immunohistology shows high levels of citrullinated proteins in 
pulmonary macrophages and smoking increases such citrullinated proteins in broncho-
alveolar lavage fluid (Makrygiannakis et al 2008). However citrullinated proteins can 
also be present in context of other diseases or even in clinically normal lungs (see 
Catrina AI et al 2014). Thus, risk from smoking might be more complex than via PADI 
induction, and may include promotion of epigenetic alterations notably DNA 
methylation with inflammatory potential (Tsaprouni et al 2014).  Perhaps the location of 
citrullination and the stochastic combination of altered peptides, innate leukocyte 
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subsets and mucosal inflammation conspire a permissive microenvironment for the 
creation of ACPAs. High-resolution CT studies demonstrate associations between 
ACPA formation and bronchial thickening in the pre-RA stages and support the idea 
that inflammatory responses are required (Reynisdottir et al 2014).  More recent studies 
have shown signs of local inflammation in bronchial tissues of untreated RA patients 
(Reynisdottir et al 2016). Using B cell barcoding techniques, the frequency of 
circulating IgA plasmablasts was found to be elevated in at risk subjects without RA 
who are ACPA positive providing further evidence for a mucosal origin for at least a 
proportion of the autoimmunity detected in RA (Kinslow J et al 2016). 
 
The relationship between the microbiome and RA has been suspected for many years 
and supported by pre-clinical studies. For example, arthritis susceptibility and severity 
in a variety of rodent strains is decreased when maintained germ-free or in 
environments with a restricted bacterial flora (Lui et al 2016).  These data suggest that 
bacteria provide complex adjuvant functions that enhance autoimmunity, either directly 
(e.g., bacterial cell walls or lipopolysaccharides) or by critically altering the 
immunoregulatory mucosal environment.  The latter could support particularly the 
generation of type 17 responses implicated in several animal models of RA (Miossec & 
Kolls 2012). 
 
In humans, inflammation of the oral mucosa, particularly periodontitis, is associated 
with increased susceptibility to RA. The most common bacteria implicated in 
periodontitis is P. gingivalis, since it can express PADI. P. gingivalis could potentially 
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citrullinate peptides in the oral mucosa that, in the context of inflammation, could 
promote ACPA generation (Wegner et al 2010).   While this concept is attractive, a 
clear association between P. gingivalis compared other bacteria is not consistently 
observed in unbiased microbiome studies. More recent data suggest that P. gingivalis or 
other bacteria could act, instead, by ligating Toll-like receptor 2 (TLR2) (de Aquino et 
al 2014). This process could increase IL-1 production and stimulate local Th17 cell 
differentiation.  An intriguing recent study identified that A. actinomycetemcomitans 
initiates hypercitrullination through the effect of a toxin, leukotoxin A (LtxA), mediated 
on neutrophils and was detected in RA patients’ oral microbiome wherein it could act as 
a bacterial trigger to disease (Konig et al 2016). 
 
In the colon, Prevotella copri species were enriched in an unbiased analysis of the 
gastrointestinal microbiome in early RA patients. Bacteroides species were decreased in 
the same patients (Scher et al 2013).  While not fully understood, the over-
representation of Prevotella was not observed in chronic RA or in other forms of 
arthritis.  Subsequent studies in the Chinese population have extended these 
observations to include novel microbial species, and demonstrated common expression 
in oral and GI mucosal sites in individuals that, remarkably, was correlated with ACPA 
levels and CRP.  Moreover further alterations in the microbiome occurred upon 
therapeutic immune modification (Zhang et al 2015). 
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Epigenetics: Integrating environmental stress and the genome 
Epigenetic modifications decorate genomic DNA and contribute to regulation of gene 
expression. The role of these marks had been widely viewed as key determinants of 
orderly gene expression during development as well as lineage-dependent RNA 
transcription throughout life. Their contribution to pathogenesis is now more clearly 
understood in many diseases, especially cancer. A variety of epigenetic mechanisms 
have been implicated in RA, including DNA methylation, histone modification, and 
microRNA expression.  Because the science of epigenetics in autoimmunity is still 
relatively young, it is uncertain whether some or all of these disease-specific alterations 
are inherited, develop during life due to stochastic exposures, cause disease or are 
actually caused by disease. Regardless, stable epigenetic marks have been identified in 
RA that alter cell function and permanently imprint some lineages, most notably 
synovial fibroblast-like synoviocytes (FLS). 
 
Most information on epigenetics in RA comes from studies of RA joint samples, 
including synovial tissue and FLS. Candidate gene approaches showed that the IL6, 
CXCL12, and EFNB1 promoters are hypomethylated in rheumatoid FLS while others, 
like DR3, EBF2, and IRX1 are hypermethylated (Karouzakis et al 2011).  Genome-wide 
approaches have identified a large number of differentially methylated loci in RA FLS 
compared with normal or osteoarthritis (OA) FLS (Nakano et al 2013). The methylation 
pattern in RA FLS is stable over many cell passages in tissue culture and involves genes 
and pathways related to cell adhesion, matrix regulation, immune function, and cytokine 
signaling. While synovial cytokines can transiently alter the methylome by regulating 
 14 
DNA methyl transferase (DNMT) expression, the changes are reversible in culture and 
suggest that cytokines alone are not solely responsible for the ex vivo profile observed 
(Nakano et al 2013).  The cells, therefore, appear to be “imprinted”, which could 
contribute particularly to the persistent aggressive phenotype of RA FLS. 
 
The functional relevance of differential methylation was confirmed for several 
candidate genes identified via integrative analysis of various ‘omics platforms. For 
example, the development gene LBH was identified because it has several associated 
RA-associated SNPs and differentially methylated loci (DMLs) (Hammaker et al 2016).  
LBH regulates the cell cycle - a functional SNP in an LBH enhancer was identified 
adjacent to a DML in FLS, and modification of the enhancer methylation status altered 
LBH transcription (Ekwall et al 2015).  In addition, a DML in PTPN11, the gene 
encoding the oncogene SHP2, led to discovery of a novel intron enhancer that regulates 
PTPN11 expression and contributes to high levels of SHP2 in RA FLS (Zhang et al 
2016). In future, incorporating epigenetic marks into the systematic analysis of cell 
function should help identify key pathogenic genes and provides a rich source of 
potential therapeutic targets.  
 
We still do not know when in the evolution of RA the epigenetic imprinting occurs. 
Recent data in FLS from patients with early RA (<1 year of symptoms) show that they 
also have an abnormal methylation pattern. However, the early RA methylome can be 
distinguished from late RA, especially for pathways related to cell growth and 
differentiation (Ai et al 2015). DNA methylation signatures in RA FLS probably occur 
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very early or even antedate clinical disease. However, it is not static and can evolve 
over time based due to synovial inflammatory environment. 
 
Perhaps even more intriguing, DNA methylation patterns, as well as transcriptomes, can 
vary between joints (Ai et al 2016).  Early studies using histology and 
immunohistochemistry suggested that the various joints involved with RA are similar. 
However, recent studies show that the DNA methylation patterns and transcriptomes 
differ between RA hip and knee FLS (Ai et al 2016). Of interest, the pathways involved 
are related to therapeutic targets, including IL-6-JAK-STAT signaling. It is not clear if 
cells are imprinted elsewhere and then migrate to the joint, or whether they attain a local 
phenotype after arriving. These data provide a possible explanation why some joints 
improve in RA while others do not when patients are treated with a given targeted 
agent.  
 
Sequencing studies suggest that the pattern of microRNA (mir) in RA compared with 
OA leukocytes and FLS exhibit global differences in expression. A growing number of 
mirs have been evaluated using a candidate gene approach. One example is mir124a, 
which is dysregulated in RA and can suppress cell cycle and chemokine gene 
expression. Increasing mir124a levels in RA FLS suppresses MCP-1 production 
(Nakamachi et al 2009).  On the other hand, mir203 overexpression increases MMP and 
IL-6 expression (Stanczyk et al 2011), while mir155 knockdown decreases the same 
genes expression in RA FLS. Mir155 is also implicated in monocyte activation and 
cytokine production in part via regulation of TLR signaling (Kurowska-Stolarska et al 
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2012).  Mir16, mir124a, mir202, mir134a, mir23, mir346, and mir15a and perhaps 
several others are differentially expressed in RA derived cells, although their pathogenic 
role still needs to be defined (Bottini & Firestein 2013).  
 
There is considerably less genome-wide information on histone marks in RA. There are 
a variety of ways that histones can be modified, including methylation, acetylation and 
citrullination. Histone deacetylases, which remove acetyl groups and remodel 
chromatin, are expressed in RA FLS and can regulate their function (Huber et al 2007). 
For example, induced HDAC1 or 2 deficiency increases p53 tumor suppressor gene and 
matrix metalloproteinase 1 (MMP1) expression in RA synovial cells (Horiuchi et al 
2009). Pro-inflammatory cytokines can increase HDAC1 expression in FLS and 
contribute to chromatin remodeling. HDAC inhibitors suppress adjuvant arthritis in rats 
and collagen-induced arthritis in mice, supporting the notion that histone modifications 
can participate in inflammatory joint disease (Joosten et al 2011).  
 
Pre-RA: an evolving immunologic response? 
As noted before, protein modification through citrullination is actually common, 
especially in the context of inflammation or stress. What is strikingly different in RA is 
the generation of antibodies against these epitopes, likely arising due to the unique 
properties of the binding pocket of RA-associated HLA-DR alleles and presumably 
other regulatory deficits (e.g. in T cells themselves) that permit emergence of 
autoreactivity over time. The teleologic explanation for induction of PADIs in normal 
immune responses is not known. PADIs have other potential functions that regulate cell 
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migration and gene expression through citrullination of chemokines and histones 
(Christophorou et al 2014).  PADI2, for example migrates to the nucleus and probably 
modifies many proteins involved in gene expression. Thus, protein citrullination could 
have a variety of functions that regulate homeostasis and cell responses to stress.   
 
The presence of citrullinated peptides in the lungs or other mucosal sites could thus 
represent the “original sin” in a pathway that ultimately leads to inflammatory joint 
disease. ACPAs, along with other antibody systems are detected years or perhaps even 
decades before clinical disease is apparent. Over time, the serum levels of ACPAs 
gradually increase over time and reach a peak at the time of disease onset through the 
first year of symptoms. A concomitant rise in blood chemokines and cytokines and 
other altered metabolic parameters suggest an ongoing and gradually accelerating 
subclinical systemic inflammatory pathology (Deane et al 2010). APCA specificities at 
all stages are quite broad, and increase during the “pre-RA phase”. The specificity of 
antibodies varies widely but include citrullinated epitopes on fibrinogen, vimentin, 
fibronectin, collagen, enolase, histones and many others (Anzilotti et al 2006).  There 
does not appear to be a single dominant specificity of ACPA, nor a particular pattern 
that predicts disease onset, phenotype or severity (Van Beers et al 2013).  Notably, in 
patients with early undifferentiated inflammatory arthritis, ACPAs can predict 
individuals who will progress to RA. 
 
In established disease, ACPAs are present in the serum of 80% to 90% of RA patients 
and are independently associated with greater disease activity, extra-articular 
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manifestations and joint damage. The antibodies alone are not especially pathogenic and 
do not cause arthritis when injected into normal mice. However, they can exacerbate 
disease in mice with arthritis, perhaps because of the presence of citrullinated substrates 
that can ultimately lead to local complement fixation. They likely act together with 
rheumatoid factors (RFs), which are autoantibodies that bind to the Fc portion of IgG. 
ACPAs are more sensitive and specific for RA than RFs, with specificity approaching 
90%. ACPAs are also present in nearly 20% of unaffected first-degree relatives and 
more than 10% of more distant relatives in Native American RA patients (El-gabalawy 
et al 2009).  ACPAs and RFs are also produced by synovial tissue B cells and can be 
detected in synovial fluid, suggesting that they could play a role in local innate 
immunity activation and complement fixation. Evaluation of the phylogenetic tree of RF 
producing cells from the synovium suggests that affinity maturation occurs in the joint 
(Randen et al 1992). 
 
A subset of patients with RA develops antibodies against other classes of modified 
proteins. For example, lysine and cyanate are converted to homocitrulline and can form 
neo-epitopes through non-enzymatic processes analogous to conversion of arginine to 
citrulline, giving rise to anti-carbamylated protein antibodies (ACarPs) present in a 
minority of patients with RA, including about 30% of ACPA- patients (Shi et al 2011). 
A variety of substrates are cambamylated and can lead to antibody formation with 
multiple specificities, such as fibronectin. As with ACPAs, they are observed about 
40% of RA patients prior to the onset of clinical synovitis (Shi et al 2014).  Like 
ACPAs, the ACarPs do not cause arthritis, but immunizing mice with carbamylated 
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peptides is arthritogenic, and transferring lymphocytes from immunized animals can 
transfer disease to naïve mice (Mydel et al 2010).  Autoantibodies that identify 
acetylated proteins have also been described (Juarez et al 2016).  Finally there are data 
that challenge the notion of loss of tolerance to citrullination as a definitive early event 
– e.g. anti-native RA33 and citrullinated RA33 were detected as a continuum in a recent 
analysis with native reactivity dominant in earlier disease (Konig M et al 2016).  Further 
sequential studies of detailed antibody profiles against the spectrum of the ‘citrullome’ 
in RA would be helpful in resolving these issues. 
 
Evolution from a high risk state to clinical synovitis 
The foregoing demonstrates that in high-risk individuals with a characteristic genetic 
(and possibly epigenetic) background, stochastic events especially at mucosal surfaces 
can lead to protein modification and ultimately antibody formation recognising altered 
peptides. The site of antibody production could either be at the site of stress, or in 
lymphoid organs defined by dendritic cells that process arthritogenic peptide at mucosal 
surfaces and migrate centrally to relevant draining lymph nodes. Lymph nodes in pre- 
and early RA are not normal (Rodríguez-Carrio et al 2016).  By definition however, 
disease emerges in the joints.  That ACPAs, rheumatoid RFs, ACarPs and perhaps other 
antibody systems do not typically lead to inflammatory joint disease per se suggests that 
a “second hit” is required, at least in model systems for tissue localization.  
 
The nature of this second signal is not well defined but could comprise some 
combination of vascular, neuro-regulatory, microtrauma, or transient infection 
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dependent pathways. In addition, there have long been suggestions that articular 
infections e.g. Epstein-Barr virus could further contribute (Tan & Smolen 2016). In 
animal models, the formation of immune complexes can trigger synovitis. The inciting 
complexes do not have to be specific for altered peptides but can actually be irrelevant; 
even immunocomplexes with antibody and horseradish peroxidase is sufficient in some 
mouse models. Thus, a variety of random tissue insults (e.g. microtrauma, viral 
infection) could lead to synovial vascular activation in the presence of the requisite size 
and charge of complexes that permits Fc receptor engagement in the synovium. 
Triggered synovial innate cells like mast cells could release vasoactive mediators and 
increases antibody access to the joint. Complement activation across this range of 
effector pathways could act to accelerate this response. Other mechanisms like Toll-like 
receptor engagement or triggering via various danger sensing molecules, could 
theoretically cause a similar cascade.  Recent data suggest a potential role for ACPAs 
beyond immune complexes depending upon their chemical properties and cellular 
specificity. Intriguing studies suggest that ACPA recognition of osteoclast (OC) 
membrane epitopes e.g. citrullinated vimentin can promote osteoclastogenesis – thus an 
early route to articular involvement via systemic ACPA expression may be via local OC 
activation (Harre et al 2012). Moreover one consequence of ACPA OC binding is the 
induction of pain and release of IL-8 providing an enticing route to subsequent 
leukocyte recruitment and the imitation of a vicious cycle of articular inflammation 
(Krishnamurthy et al 2016). In addition ACPAs most likely to progress disease exhibit 
an altered glycosylation state (Rombouts et al 2015), though the functional 
consequences of these observations remains less well understood. 
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Once in the joint in established disease, autoantibodies may bind to antigen, fix 
complement, release chemotactic fragments and initiate a cascade of events that 
activates other resident cells, recruits new innate and adaptive immune cells and 
promotes stromal cell activation (Tan & Smolen 2016). These, in turn, can produce 
additional cytokines and chemokines to create a positive feedback loop and ultimately a 
self-perpetuating process with inadequate negative regulators required for termination 
(Figures 2 &3). The joint is uniquely susceptible to promote such a series of events. For 
example, the vasculature is already porous and facilitates ingress of proteins and cells. 
The synovial intimal lining, which forms the surface of the synovium and contains 
macrophage-like and fibroblast-like synoviocytes (FLS) are not an effective barrier 
because there are no tight junctions or an organized basement membrane. Once in the 
joint, antibodies can be displayed on cartilage to promote complement fixation. Murine 
models involving antibodies to type II collagen or glucose-6-phosphate isomerase are 
particularly effective at inducing synovitis because of their propensity to bind to these 
articular surfaces. The former is pathogenic because it is critical component of hyaline 
cartilage and the latter most likely adheres to negatively charged cartilage surfaces 
(Matsumoto et al 2002). 
 
One of the important lessons of this prolonged and step-wise pre-RA process is that the 
sequence of events does not require autoimmunity against native proteins in the earliest 
stages. The immune response could be more properly considered a normal appropriate 
adaptive immune response to altered antigens that are viewed as “foreign” because they 
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were not generated during thymic development and pathogenic T cells could not be 
deleted. The high-risk individuals with ‘unfortunate’ HLA-DR alleles happen to bind to 
these modified proteins more avidly than the native molecule. Later, perhaps through 
epitope spreading, more traditional autoimmunity develops and leads to production of 
antibodies commonly detected in chronic RA that bind to collagens and many other 
native proteins. 
 
Considering an early role for stromal cells as important pathogenic factors? 
Compelling data implicate adaptive immune responses in the pathogenesis of RA, but 
alternative hypotheses propose that stromal elements also can play a critical role. Early 
pioneering studies by Gay and colleagues showed that FLS assume an autonomous 
aggressive phenotype that is maintained for months after removal from the patient 
(Muller-Ladner, et al 1997). These data and the destructive potential of fibroblasts led to 
the notion that FLS are imprinted or permanently altered in RA and could either initiate 
or exacerbate disease (Firestein, 1996, Firestein and Bottini, 2013). Numerous 
mechanisms for “partial transformation” have been implicated, including abnormal 
DNA methylation (see below), somatic mutations in various genes (e.g., p53, 
mitochondria, vimentin), defective PTEN expression, and high levels of sentrin (Pap et 
al, 2000, Franz et al 2000, Firestein et al 1997, and reviewed in Firestein and Bottini, 
2013). In addition, activated FLS can play an active role in antigen presentation and 
contribute to local adaptive immune responses (Tran et al 2007). Finally, the synovial 
fibroblasts are not a uniform population but segregate into different phenotypes based, 
in part, on their cytokine profiles (Croft et al, 2016). The role of mesenchymal cells in 
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disease initiation and progression represents an interesting therapeutic opportunity 
because no approved agents currently target these cells (see Figure 1 for alternate 
models of contribution of stromal cells and autoimmunity in a notional hierarchy – note 
that these are not mutually exclusive).   
 
Pathologic characteristics of clinical synovitis 
The histologic appearances of RA synovitis have been extensively characterized. 
Normal synovial membrane is relatively acellular comprising scattered macrophages 
within a stromal tissue curated by FLS and sparse blood vessels. Its primary function is 
to lubricate and nourish the articular surface, which lacks a blood supply.  During the 
pre-RA phase, the synovial appearance is not markedly altered; biopsy studies or 
ACPA+ arthralgia are remarkably benign, with no obvious leukocyte infiltrates, nor 
transcriptional changes (de Hair et al 2014).  However with the onset of clinically 
evident articular swelling (including that detected by MRI or power-Doppler ultrasound 
imaging) the synovium assumes a rather different appearance (reviewed by McInnes & 
Schett 2011).   The lining layer, normally 2-3 cells thickness expands up to 10-12 cells 
depth, comprising macrophages and FLS.  Underlying this is a dense interstitial cellular 
infiltrate containing cells characteristic of innate, e.g., macrophages, dendritic cells, 
mast cells, natural killer (NK) cells, innate lymphoid cells, and of adaptive responses 
e.g. B and T lymphocytes, and plasma cells. This is associated with significant 
neovascularization, with some lymphangiogenesis.  
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The immunologic properties of RA synovium are now well characterized. Synovitis 
studies relied originally on arthroplasty-derived tissues, that were usually by definition 
end stage disease, but have been expanded by the use of synovial biopsies obtained via 
arthroscopy or ultrasound methodologies facilitating investigation of all stages of 
disease (Kelly et al 2015). Macrophages, mainly of M1 phenotype, are potent 
contributors to effector pathology by virtue of release of cytokines (e.g. TNF, IL-1, IL-
6), chemokines, MMPs, vasoactive peptides, oxygen and nitrogen intermediates.  
Numerous activation pathways of macrophages have been described including TLR 
ligands, soluble proteases (via PAR2), cholesterol derivatives and immune complexes 
(Figure 2).  The latter, containing RF and ACPA, act via FcgR1 and FcgR3 that are 
highly expressed on synovial macrophages. Coincident binding of ACPAs to soluble 
citrullinated TLR ligands e.g. cit-Fibronectin may enhance these effects – by this model 
ACPAs can bind both TLR and FcR on the same cell to optimize activation (Sokolove 
et al 2011) leading to high levels of cytokine release.  The glycosylation status, 
particularly sialylation, of ACPAs also alters their capacity to promote inflammation 
(Rombouts et al 2015). Cognate interaction with memory T cells is a further intriguing 
activation pathway – acting via a non-antigen dependent manner, the cytokine rich 
synovial milieu, particularly IL-15, IL-7 and IL-6, can induce integrin and Ig-
superfamily dependent interactions between CD45RO+ memory T cells and 
macrophages to drive subsequent macrophage cytokine and chemokine release 
(McInnes & Schett 2007)  
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Most interest in the contribution of T cells has however focused on their antigen-driven 
role in initiation and perpetuation of disease.  CD45RO T cells are abundant in synovial 
membrane and exhibit an activated phenotype.  Fascinating studies have established that 
RA peripheral blood CD45RO naïve T cells exhibit unique anabolic metabolic features 
characterized by low glucose metabolism, lower icATP levels associated with PFKFB3 
deficiency that may play a role in their relative senescence and likely therefore their 
chronic activation state (Zhen et al 2013; Yang et al 2016).  Synovial biopsies from very 
early RA contain expanded T cell clones that likely represent enrichment for self-
reactive (or least altered-peptide reactive) clones – this feature disappears with disease 
progression presumably reflecting dilution of these clones by secondarily recruited 
polyclonal memory T cells (Klarenbeek et al 2012). The differentiation state of the 
synovial T cell is also uncertain.  Murine arthritis models strongly suggest a pivotal role 
for T helper 17 (Th17) cells (Miossec & Kolls 2012: Lubberts 2015).  Human data have 
rather challenged this proposition though no firm conclusions can yet be drawn as the 
critical pre-RA phase could well be Th17 driven but not manifest in the effector stages 
of disease amenable to direct examination.  Nevertheless, one report suggests that 
cytokine profiles in lavage fluid from early RA are paradoxically rich in IL-4, IL-13 and 
IL-15, whereas those T cells detected in established disease have features of both Th1 
and Th17 (Raza et al 2005).  A recent study in which citrullinated tetramer responses 
were explored in RA patients found most T cells that were cit-specific were of Th1 
phenotype (Snir et al 2011).  IL-17 targeting therapeutics including IL-17A and IL-
17RA inhibitors have as yet not been particularly effective in established RA trials 
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despite remarkable responses being achieved in psoriasis (Langley et al 2014) and to 
some extent spondyloarthropathies (McInnes et al 2015).    
 
Future studies using single cell based sequencing methodologies and the availability of 
detailed transcriptional definitions of T cells are underway to facilitate characterization 
of T cell subset differentiation in the phases of RA development.   Understanding those 
factors that define T cell differentiation in RA or perhaps other cell lineages that could 
contribute to the evolution of this unique disease might critically important because the 
detection of Tregs in synovium has also been extensively documented - clearly their 
functional impact is insufficient, or they may have a functional deficit.  Some evidence 
suggests that inadequate Treg function is characteristic of RA and is corrected by TNF 
blocker therapy (Byng-Maddick et al 2015). However, it is not clear if this defect is 
primary or secondary. Re-establishing local T cell homeostatic balance via expansion or 
recovery of Treg function is an attractive approach to future therapeutics particularly as 
we seek restoration of tolerance as the clinical target (Rossetti et al 2016; Benham et al 
2015).  
 
Clearly autoantibody production is a hallmark of RA. B cell lineages at each stage of 
development are detected in synovium, include the presence of mature plasma cells.   
The synovium provides a cytokine rich milieu for B cell survival, e.g., via BAFF, 
APRIL, IL-6 expression.  A particular role for FLS (which are the primary source of IL-
6 in the RA synovium) in maintaining this milieu has recently emerged exemplifying 
the tissue dependency of the articular immune response (Bombardieri et al 2011).  In a 
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proportion of tissues there are ectopic lymphoid structures (ELS) that have been 
associated with more rapid erosive progression.   Prior studies demonstrated that ELS in 
RA tissue contain the enzymatic machinery necessary for antigen-driven selection, 
differentiation, somatic hypermutation and class switching (Pitzalis et al 2014). 
Recently single cell sequencing of synovial B cells suggests extensive self-reactivity 
particularly to citrullinated histones H2A and H2B and other citrullinated self-proteins – 
neutrophil could form a focal event permitting expansion of such clones (Corsiero et al 
2015).   Thus, in addition to antigen presentation, autoantibody formation and release, B 
cells should be considered important sources of local antigen presentation, and of 
cytokine release into the milieu. 
Finally it is vital to consider the role of the local stromal tissues in synovium.  FLS have 
been long recognized to contribute to the matrix deposition and tissue remodeling that 
characterizes RA (Zvaifler & Firestein 1994).  They exhibit anchorage independence, 
migratory activity (potentially even between joints), local proliferation and release high 
levels of MMP and TIMPs (Tissue inhibitors of metalloproteinases), cytokines and 
chemokines together with collagens and other ECM components (Filer 2013).  They 
appear to be particularly dependent upon cadherin 11 for their effector function (Kiener 
et al 2009).  As such they should be considered a critical component of the RA 
inflammatory response rather than as responding bystanders. Other studies suggest the 
existence of FLS subsets although the functional significance of these remains 
uncertain. Further complexity is emerging since FLS exhibit distinct features even 
across different diarthrodial joints e.g. hips and knees described above.  FLS may also 
migrate across anatomically discrete articular sites (Lefevre et al 2009).  Presumably 
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reflecting the epigenetic changes described above FLS thus play a critical role in 
recruiting, retaining, activating and sustaining leukocytes e.g. via type 1 interferons, 
CXCL12 (SDF-1) in the synovium (e.g. Perlman et al 2003).  Finally, in combination 
with endothelial cells they may become permissive for ELS formation (Pitzalis et al 
2014) further enhancing an ‘autoreactive-prone’ articular microenvironment. 
 
Articular destruction, often reflected in radiographic evidence of bone erosion, is a 
further hallmark of RA.  Mechanisms driving damage are reviewed elsewhere (McInnes 
& Schett 2007).  Briefly, FLS drive damage primarily via MMP (particularly MMP1 & 
MMP3) mediates direct cartilage damage or by promoting chondrocyte activation and 
tissue catabolism through cytokine release in concert with macrophages. IL-1, TNF and 
IL-17 are particularly relevant in this respect.   Bone damage arises from more complex 
interactions that sustain osteoclast precursor maturation mediated particularly via 
RANKL, M-CSF and TNF pathways.  Recent insights into the participation of 
sclerostin, DKK, ACPAs and other osteoclast and osteoblast co-regulators suggest the 
intriguing possibility of promoting bone healing – this has not yet been possible on the 
basis of existing therapeutics (Diarra et al 2007: McInnes & Schett 2011). Other factors 
in the synovial milieu including ACPAs are also implicated via their ability to bind 
directly to osteoclasts and promote their differentiation and activation. 
 
One further development of note is the recent observation by some groups of synovial 
tissue micro-heterogeneity in several cohort studies.  Thus, subsets of patients can 
potentially be defined by myeloid, lymphoid and stromal rich synovial pathotypes 
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(Dennis et al 2014).  The longer-term functional implications of these subsets are 
currently unclear but carry the potential to offer subtype specific therapeutics in due 
course – clinical trials are underway to test this hypothesis (Astorri et al 2015; Kelly et 
al 2015).  If confirmed this would suggest that distinct pathologic processes can induce 
pathotypes that are pathologically discrete, and of functional importance in identifying 
dominant effector pathways and tissue responses.   
.    
Lessons from therapeutic targeting as to the hierarchy of pathways and 
heterogeneity of responses 
The utility of immune targeting in RA represents a major advance in disease 
management (Smolen et al 2016; Smolen & Aletaha 2015).  Thus inhibitors of TNF and 
IL-6 are particularly potent in delivering clinical responses.  Co-stimulatory blockade 
with abatacept (CTLA4:Ig) is similarly effective, as is depletion of CD20 lineages using 
rituximab (Nam et al 2014; Schiff et al 2014). Notably, those blocking for example IL-
17, IL-1, BAFF, IL-21 and IL-20 appear less effective. More recently small molecule 
inhibitors of the JAK pathways, e.g. tofacinitib (targeting JAK1 and JAK3), and 
baricitinib (JAK1 and JAK2) have demonstrated considerable efficacy, especially if 
used in early disease (Genovese et al 2016: Lee et al 2014).  
 
Immune therapeutics have taught us much (Table): (i) critical immune checkpoints or 
functional nodes must exist within the complex synovial lesion that are amenable to 
blockade and promote collapse of the majority of the lesion; (ii) upstream immune 
dysregulation apparently manifests primarily in cytokine (especially TNF and IL-6) 
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mediated effector mechanisms; and (iii) murine models, despite offering exquisite 
mechanistic insight and proof of possibility, poorly reflect the complexity of the human 
RA state and therefore the therapeutic potential of any given agent.  Moreover the 
discrete effects of cytokine inhibitors across the wider range of chronic inflammatory 
diseases is increasingly pointing to a new molecular disease taxonomy that can be 
therapeutically defined – RA might represent a TNF and IL-6 dependent axis whereas 
psoriasis might reflect more TNF, IL-23 and IL-17 dependent pathways.  
 
The diversity of responses to highly targeted agents like cytokine inhibition, B cell 
depletion, or co-stimulation blockade suggest that RA is not a single disease entity. 
Instead, it is a syndrome with a common clinical presentation but multiple pathogenic 
pathways, any one of which (or combination) might be relevant for a particular patient 
(Firestein 2014). One of the key challenges going forward will be how we can stratify 
patients so that we can make better treatment selections. Thus far there are no studies 
that have separated responder RA populations to distinct interventions.  A variety of 
molecular and cellular profiling approaches in peripheral blood have not been 
successful as yet. As noted above, preliminary studies suggest that synovial histologic 
patterns might correlate with responses to therapy, although other careful assessments of 
synovial structure and biomarkers have not demonstrated sufficient power for clinical 
utility (Dennis et al 2014).  These in turn could presage the advent of biomarkers that 
enrich for response. We also need to begin considering more robust clinical trial 
instruments to take into account joint-specific differences in clinical responses.  
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Kinetically distinct phases of immune pathway utilization as RA progresses also should 
be considered – in essence we use all immune therapeutics across the various phases of 
RA development without consideration to the dominant pathogenesis at that time point 
(McInnes et al 2016). Immunologic adaptation is a characteristic of chronic infectious 
responses and it seems plausible that similar alterations in effector pathways will evolve 
as damage accrues in patients. Should we now consider ‘pathogenesis-appropriate’ 
timing of therapeutic interventions? For example, could there be a role for immune 
tolerance inducing therapies in very early RA, or even pre-RA?  This supposes that pre-
RA can be identified in a meaningful population and at a stage when immune 
homeostasis or re-programming can be achieved, and that molecular outcome measures 
can be derived to define therapeutic success. Various therapeutics are being explored in 
this respect, including B cell depletion or co-stimulatory blockade in high risk 
populations.  The PRAIRI study administered a single dose of rituximab to people at 
high risk of developing RA – formal reporting of outcome is awaited (NTR2442 
Netherlands Trial Register).  A similar study is ongoing in which abatacept is being 
given to high risk pre-RA (APIPRA Study; ISRCTN46017566). Finally a broader 
approach to identification of pre-RA comprises the StopRA study in which 
hydroxychloroquine is being given to health subjects with an elevated ACPA 
(NCT02603146). Finally, exciting cell transfer clinical trials using tolerogenic dendritic 
cells, with thus far encouraging results in terms of immune function modulation are also 
ongoing (Benham et al 2015).  
 
Processes driving co-morbidities 
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RA is associated with increased cardiovascular risk, metabolic syndrome, psychosocial 
deficit, including psychiatric disease, osteoporosis, and increased cancer rates.  The 
mechanisms underlying these are increasingly understood to depend on cytokines and 
other circulating immune moieties, primarily using immune therapeutics as molecular 
scalpels.  For example, IL-6 and to some extent TNF directly regulate cholesterol 
metabolism, such that active RA is associated with paradoxical low cholesterol levels 
that are replenished with effective therapy – the latter appears to operate via direct IL-6 
mediated, STAT3 dependent modulation of cholesterol ester catabolism (Charles-
Shoeman et al 2015: Robertson et al 2014).  Similarly the atherosclerotic lesion and RA 
synovium exhibit remarkable similarities leading to the suggestion that TNF and IL-6 
driven pathways may enhance the progression of vascular disease.  TNF inhibition in 
patients leads to reduced vascular dysfunction and to improve vascular mortality 
commensurate with this notion (McKellar et al 2009). Moreover RA atherosclerotic 
plaques exhibit exaggerated cytokine expression compared to non-RA controls  (Ahmed 
et al 2016).  Similarly circulating TNF, RANKL and IL-1 are implicated in systemic 
osteoporosis (McInnes & Schett 2011), and TNF has been implicated in the 
hippocampal dysfunction that likely underlies depression in RA (Krishnadas et al 2016).      
 
Concluding remarks 
RA represents a remarkable example of successful immunologic interrogation of tissue 
culture cells, pre-clinical models and human translational studies that has delivered 
enormous therapeutic advances. The penumbra of these advances has also benefited 
many other immune-mediated disease, such as psoriasis, spondyloarthropathies, 
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inflammatory bowel disease (IBD) and inflammatory eye disease. It has taught us much 
about immune pathogenetic mechanisms in the context of human autoimmunity and 
chronic inflammation, not least in unraveling the complex multi-hit sequence of events 
that ultimately overcome immune homeostasis to manifest as tissue destructive disease. 
Despite such successes there remains much unmet need, not least in the current absence 
of the capacity to predict, prevent and cure the disease or even predict which patients 
respond to a particular therapy.  It is clear that further pathogenetic discovery must drive 
such progress and lead ultimately to the delivery of agents with homeostatic activity, 
used within a precision medicine-based therapeutic culture.. 
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Legends to figures 
 
Figure 1 
Depicting the sequence of events leading to the development of clinically detectable 
rheumatoid arthritis – at least two potential models are depicted.  In model A, a pre-RA 
phase comprises early generation of autoantibodies (ACPAs) that can bind post-
translationally modified self-proteins, particularly via citrullination.  This is followed by 
amplification of the range of specificities of ACPA and by the elaboration of cytokines 
and chemokines, complement, and metabolic disturbance in the months prior to clinical 
development of disease.  A transition event that requires a ‘second hit’, as yet poorly 
understood permits the development of synovitis.  The latter is characterized by frank 
inflammation, stromal compartment changes and tissue modification leading to articular 
damage.   In model B, which is not mutually exclusive, there is an early interaction 
between innate immune activation and stromal factors that lead to stromal cell 
alteration, including epigenetic modifications that initiate a cycle of inflammatory 
stromal mediated damage.  Autoimmunity can arise as a result of these interactions that 
in turn can conrtibtue directly or in an amplification loop to disease perpetuation.  
 
Figure 2 
Myeloid cells, particularly macrophages are central to the perpetuation of disease 
pathogenesis.  Pathways that can activate macrophages in RA synovitis are shown that 
promote cytokine release – IL-6 and TNF in particular, and probably GM-CSF, are of 
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central importance as defined by the clear therapeutic benefits achieved upon their 
inhibition. 
 
Figure 3 
Mechanisms that drive the chronicity of RA.  Distinct pathways combine to mediate 
failed resolution of disease – these include adaptive, innate and stromal components 
with additional impact of the systemic features of disease.  The latter may be both 
consequence of the chronic inflammation or could promote the chronicity e.g. via 
creation of pro-inflammatory lipid profiles, promotion of bone remodeling and 
secondary osteoarthritis. 
 
Table 
The major drug classes that have been employed in the treatment or investigation of RA 
and that have been informative for pathogenesis studies are depicted herein. 
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Table  Major drug classes that have been informative of the pathogenesis of RA 
 
Immune Target Drugs Key modes of action 
TNF Adalimumab 
Etanercept 
Golimumab 
Certolizumab 
Infliximab 
Biosimilars 
 
Reduced endothelial, stromal cell & 
chondrocyte activation 
Reduced osteoclast differentiation / 
activation 
Modified cellular migration 
Reduced cytokine expression e.g. IL-6 
Reduced metabolic / CVD risk 
 
IL-6 Tocilizumab 
Multiple Ab in 
  development 
 
 
Reduced endothelial, stromal cell 
activation 
Reduced osteoclast activation 
Reduced cytokine / chemokine 
expression  
Altered lipid metabolism  
 
 
Co-stimulation 
(CD28 - CD80/86) 
Abatacept 
 
Reduced T cell activation 
Diminished dendritic cell activation, 
cytokine production and antigen 
presentation 
Reduced osteoclast activation 
 
B cell depletion  
(anti-CD20) 
Rituximab 
 
Depletion of CD20+ B cell lineages, 
sparing plasma cells. 
Reduced cytokine production 
Reduced antigen presentation 
 
JAK inhibitors Tofacitinib 
Baricitinib 
Multiple compounds 
   in development 
 
Inhibition of pivotal cytokine receptors 
with predictable downstream effects.  
JAK1, JAK2 and JAK3 thus far 
targeted 
 
IL-1 Anakinra 
 
Decreased endothelial cell, stromal cell 
activation 
Decreased cellular migration 
Altered T cell differentiation 
Innate immunity activation 
 
Other cytokines 
(GM-CSF, IL-17, and 
others) 
Multiple 
 
Multiple 
 
 
